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Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant
glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled
drug derivatives. Here, we report a newmethodology usingmatrix assisted laser desorption ionizationmass
spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular
labeling. In studies summarized here, we first validate heme as a simple and robust MALDIMSI marker for
the lumen of blood vessels in the brain.We go on to provide three examples of howMALDIMSI can provide
chemical and biological insights into BBB penetrance andmetabolism of smallmolecule signal transduction
inhibitors in the brain – insights that would be difficult or impossible to extract by use of radiolabeled
compounds.
T
he specialized microvasculature of the postnatal brain acts as a physiological wall restricting the diffusion of
molecules and circulating cells between the blood and the central nervous system (CNS). The physiological
purpose of this blood-brain barrier (BBB) is to protect the CNS from toxins and pathogens. However, this
same selective permeability impedes the delivery ofmany potentially useful drugs into the interstitial spaces of the
brain1–3. Accurate determination of the BBB permeability for potential drug candidates is therefore essential in
drug discovery programs, both for drugs targeting the CNS as well as for drugs that should remain outside of the
nervous system to limit side effects. Drug concentration in cerebrospinal fluid (CSF) is commonly used to
estimate drug penetration into the brain. However, the CSF is a specialized fluid produced by the choroid plexus
and is not at all representative of the interstitial milieu of the brain4,5. Moreover, the choroid plexus is separated
from the blood by the choroid epithelium, creating a blood-CSF barrier, which is distinct from the BBB created by
the vascular endothelium.
The visualization of drug distribution is typically accomplished by monitoring the distribution of radiolabeled
drug derivatives in blood plasma relative to organs and tissues of interest6,7. However the genesis of radiolabeled
drug derivatives is an expensive process. Moreover, this approach is vulnerable to false negatives (active drug
metabolites missing the radiolabel) and false positives (inactive drug metabolites retaining the label)8.
Computational approaches complemented by microdialysis and other methods have been used to predict and
quantify BBB permeability. However, the utility of these methods is limited9–12.
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDIMSI) has been used to image
drug molecule and metabolite distributions in tissue sections13–15. The only sample preparation required for this
label-free approach is matrix deposition. Chemical images can be acquired within minutes to hours depending
largely on the targeted spatial resolution. The images of multiple molecules in a given tissue section can be
obtained simultaneously using MALDI MSI, allowing for accurate image co-registration.
We show here that multiplex imaging by MALDI MSI can be exploited to determine BBB permeability. By
simultaneous imaging of drug and/or drugmetabolite together with heme (delineating the lumen of blood vessels
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in the brain) a temporal/spatial map of drug transit into the brain
parenchyma can be developed. In studies summarized here, we use
fluorescence microscopy together with MALDI MSI to validate the
concept. Three ‘‘case studies’’ of anti-cancer small molecules with
differential BBB permeability are used to illustrate insights into the
distribution and metabolism of drugs within the interstitial spaces of
the brain that cannot be obtained by other methods.
Results
Validation of heme as a biomarker of vasculature in the brain.
Heme, as a cofactor of hemoglobin in red blood cells, is mainly found
within the lumen of blood vessels. As shown in Figure 1, heme can be
used to visualize the lumen of blood vessels in the brain using
MALDI MSI. Validation was achieved by showing co-registration
of heme with fluorescein (Fig. 1) and FITC (Supplementary Fig.
2) - two widely accepted fluorescent dyes that do not transit
the lumen of blood capillaries16,17. Interestingly, a lateral ventricle
delineated by fluorescein in both MALDI MSI and fluorescence
images is observed with the absence of heme detection (Fig. 1a;
yellow arrows). This is because the blood-CSF barrier, which is
composed of the vasculature around the choroid plexus, is
fenestrated and slightly more permeable than the blood-brain
barrier, thereby allowing the better transportation of fluorescein
from blood into CSF18.
Regional differences in integrity of the blood-brain barrier revealed
by MALDI MSI. BKM120 (Novartis Pharmaceuticals, Basel, Switzer-
land) is a small molecule inhibitor of pan-class I phosphatidylinositol
3-kinase (PI3K)19,20. By multiple methods including tissue distribution
of radiolabled derivatives, BKM120 traverses the BBB21. Activation of
the PI3K signaling axis, either by gain-of-function mutations in
PI3K110a or loss-of-function mutations in PTEN, is a common
event in high-grade human gliomas22,23. For all of these reasons
BKM120 is currently in phase II clinical trial for glioblastoma21.
The permeability of BKM120 through the BBB inmouse brain can
be directly visualized using MALDI MSI. For the images shown
in Figure 2, mice were dosed with BKM120 by oral gavage and
sacrificed after 4 hours. Brains were removed, sectioned and imaged
by MALDI MS for heme and BKM120 (m/z 411.2 6 0.1). Overlay
images of heme and BKM120 distributions show that a large pro-
portion of the drug signal does not co-localize with heme, suggesting
that BKM120 escapes from the brain vasculature and penetrates the
brain parenchyma. Notably however, the segregation of BKM120
from heme is not uniform throughout the brain. Rather, regional
differences in apparent integrity of the BBB are notedwithmaximum
drug penetrance seen through the plane of the lateral ventricles and
in the region of the cerebellum. These regional differences are espe-
cially apparent in three-dimensional reconstructions of MALDIMSI
images from drug-treated mice (see Supplementary Video 1).
Impact of aberrant tumor vasculature revealed by MALDI MSI.
RAF265, previously known as CHIR-265 (Novartis Pharmaceuticals,
Basel, Switzerland), is a small molecule inhibitor of the RAF serine/
threonine protein kinases24,25. Recent studies document activating
mutations in BRAF as a frequent oncogenic driver event in pedia-
tric low-grade astrocytomas (PLGAs)26. Accordingly small molecule
RAF inhibitors are plausible therapeutic agents for these tumors. As
shown in Supplementary Figure 4, RAF265 can suppress the growth
of a ‘‘genetically relevant’’ murine model of PLGA that has been
transformed by a human BRAF oncogene provided that the cells
are implanted subcutaneously. When the tumor cells are implanted
stereotactically into the brains of SCID mice, RAF265 has little if any
effect on survival.
The differential effect of RAF265 on subcutaneous versus intracra-
nial tumor implants is indicative of limited BBB penetrance.
Curiously however, MALDI MSI images at low resolution (100 mm)
shows that RAF265 actually accumulates within the intracranial
tumor implants (Fig. 3a and Supplementary Video 2). Higher reso-
lution images are needed to resolve individual capillaries and venules
within the brain. When heme and RAF265 are imaged at 25 mm so as
to resolve these individual blood vessels, it can be seen that most of the
drug is actually sequestered within the lumen of the tumor vasculature
together with heme (Fig. 3d). Notably, RAF265 does not accumulate
within the vasculature of healthy brain (Fig. 3b).
Figure 1 | (a) Comparison of heme and fluorescein images fromMALDI TOFMSI at 50 mm resolution with fluorescence image in the samemouse brain
section (10 mmthickness) with pre-injected fluorescein. i: fluorescence image of blood vessels from fluorescein (Ex-490 nm, Em-520 nm); ii: heme image
(red,m/z 616.26 0.1) fromMALDIMSI; iii: fluorescein image (blue,m/z 333.36 0.1) fromMALDIMSI (fluorescein spectra presented in Suppl. Fig. 1);
iv: overlay of heme (red) and fluorescein (blue) fromMALDIMSI; v: H&E staining of a sister section from (a) with the expanded view showing the lateral
ventricle; The yellow arrow indicates the lateral ventricle delineated by fluorescein with the absence of heme. The red arrow shows blood in the H&E
staining image. (b) Selected view of heme and fluorescein images fromMALDI MSI under 25 mm resolution and fluorescence image in the same mouse
brain section. i: fluorescence image of blood vessels from fluorescein (Ex-490 nm, Em-520 nm); ii: heme image (red,m/z 616.16 0.1) fromMALDIMSI;
iii: fluorescein image (blue,m/z 333.0 6 0.1) fromMALDI MSI; iv: overlay of heme (red) and fluorescein (blue) fromMALDI MSI; v: H&E staining of a
sister section. The arrow shows the region of blood.
www.nature.com/scientificreports
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What accounts for the accumulation of RAF265 within the tumor
vasculature? Jain and others have noted that the vasculature of many
solid tumors is swollen and engorged due to the impact of tumor
cytokines such as vascular endothelial growth factor (VEGF), result-
ing in reduced blood flow at the tumor area27,28. Within such a tumor
microenvironment, circulating drug molecules are not cleared effi-
ciently, and accumulate within the abnormal blood vessels. In accord
with this view immunostaining for blood vessel endothelial cells
(using an antibody to CD31 – Cluster of differentiation 31) reveals
numerous dilated blood vessels within the intracranial tumor
implants (Fig. 4).
MALDI FTICR imaging of drug metabolites in brain parenchyma.
Erlotinib is a small molecule inhibitor of the epidermal growth factor
receptor (EGFR) that is known to be extensively metabolized within
the liver29–34. As indicated schematically (Fig. 5) erlotinib itself
and two of its liver metabolites are biologically active; however mul-
tiple metabolites of erlotinib are biologically inert. The predicted BBB
penetrance of these various metabolites predicated upon molecular
mass and hydrophobicity is roughly equivalent. Pharmacologically
inactive metabolites such as these could, in principle, confound
studies of BBB penetrance using isotopically labeled erlotinib
derivatives.
As shown in Supplementary Figure 6we can resolve erlotinib and
four of its known metabolites from a single 60 mm MALDI Fourier
transform ion cyclotron resonance (FTICR) pixel from the liver of a
drug treated mouse at 4 hours after drug treatment. The high mass
accuracy of FTICR acquisition (,1 ppm mass tolerance) results in
confident assignment of the erlotinib (m/z 394.17613) and the meta-
bolites. A visual representation of erlotinib and these same four
metabolites within the liver of a drug-treated mouse (derived from
the data set shown in Supplementary Fig. 3) is shown in Figure 6a.
The permeability of erlotinib and its metabolites through the
blood-brain barrier was investigated in a xenograft mouse model
with human U87 glioma cells (Fig. 6b). Histopathological evaluation
of the tissue sections revealed the tumor margin on serial brain sec-
tions (Fig. 6b). High intensity heme signal was observed around the
tumor margin consistent with local disruption of the blood-tumor
barrier and hemorrhage. Erlotinib was observed to be more evenly
distributed within as well as at the infiltrative margins of the tumor
region and independently of the heme signal (Fig. 6b), indicating
that the drug molecules escape from the tumor vasculature. As
shown in Figure 6b, we can also detect one of the erlotinib metabo-
lites (M13/14) within the tumor microenvironment although
this metabolite is much less abundant than erlotinib itself. This
Figure 2 | Overlaid heme (red, m/z 616.16 0.1) and BKM120 (green, m/z 411.26 0.1) images from MALDI MSI of serial coronal sections of mouse
brain at 4-hour dosing time (dosage 200 mg/kg) used to reconstruct the 3D model in Supplementary Video 1. (BKM120 spectra presented in
Suppl. Fig. 3) H&E staining of sister sections are displayed below. Sections were collected at 500 mm intervals and imaged at 100 mm spatial resolution by
MALDIMSI. Regions that show the highest drug diffusion are sections containing the posterior lateral ventricles (v and vi), and near the Circle ofWillis in
the inferior portion of the brain (xii, xiii, and xiv).
www.nature.com/scientificreports
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differential abundance of erlotinib relative to M13/14 was also noted
in liver (see Fig. 6a) and in prior studies by Ling et al35.
Discussion
An important unmet need in drug development for CNS indications
is a method for monitoring drug transit through the BBB that is not
dependent upon molecular labeling of drug candidates. We show
here that correlation of drug and heme images by MALDI MSI
can be used to image drug permeability through the BBB.
Moreover, MALDI MSI images reveal insights into other facets of
drug delivery into brain and brain tumors that cannot not be
obtained by conventional methodology such as i) regional differ-
ences in integrity of the BBB, ii) impact of aberrant tumor vasculature
on drug penetrance, and iii) resolution of drug and drug metabolites.
The direct imaging of drug penetrance of the BBB byMALDIMSI
holds potential in screening for drug candidates targeting the central
nervous system, as well as for drugs that should remain outside the
central nervous system to minimize side effects. The 3D models
reconstructed from MS and optical images provided insight in drug
distribution as it relates to brain anatomy. Interestingly, higher con-
centrations of drugs were observed in the vicinity of the lateral ven-
tricles and the cerebellum for both RAF265 and BKM120. This
Figure 3 | (a)–(c)MALDI TOFMS images ofmouse brain tissue (10 mmthickness) for heme (red,m/z 616.26 0.1) and RAF265 (green,m/z 519.26 0.1)
distribution under 100 mm spatial resolution RAF265 spectra presented in Suppl. Fig. 5). (a) brain with PVL311 xenograft tumor with a 2-hour single
dose of 60 mg/kg RAF265; (b) control healthy brain after 2-hour RAF265 treatment; (c) control brain with PVL311 xenograft tumor but no
drug treatment. (d) MALDI TOF MS imaging of selected tumor region under 25 mm spatial resolution. Yellow color indicates overlay of heme and
RAF265. H&E staining of sister sections are displayed on the right.
www.nature.com/scientificreports
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phenomenon suggests that the therapeutic effect of these drugs on
brain tumormay vary depending on tumor location in the brain, and
invites for including the consideration of brain anatomy in defining
dosing regimens.
MALDI MSI also lends itself to more direct applications in the
context of drug development for CNS cancers. For example, the time
course of drug transit through the BBB or through the blood-tumor
barrier could be imaged in patients undergoing surgery. In the
fullness of time, MALDI MSI could move beyond imaging of drugs
per se and be used to image the cellular response to targeted ther-
apeutics in the human brain.
Methods
Tissue preparation- healthy mouse brain. Fluorescein and fluorescein 5(6)-
isothiocyanate (FITC) were used to validate MALDI MS imaging of mouse brain
vasculature using fluorescence microscopy and MALDI MSI. The mice were injected
with 400 mg/kg fluorescein sodium salt (Sigma-Aldrich, St. Louis, MO) or FITC
(Sigma-Aldrich, St. Louis, MO) in PBS from the tail vein and sacrificed after three
minutes. The mouse brain was flash frozen in liquid nitrogen and stored in 280uC
freezer. For tissue sectioning, the frozen mouse brain was mounted with minimal
amount of optimal cutting medium (OCT) compound, such that OCT did not come
into contact with the cryotome blade, and sectioned at 10 mm thickness using a
Microm HM550 cryostat (Mikron Instruments Inc, Vista, CA). The specimen
temperature was set at 219uC and chamber temperature at 220uC. Tissue sections
were thaw-mounted on indium tin oxide (ITO) coated glass slides (BrukerDaltonics,
Germany) for mass spectrometry imaging, and sister sections were mounted
independently on optical slides (Fisher, Pittsburgh PA) for histochemistry. The slides
were first analyzed using fluorescencemicroscopy, followed byMALDI time-of-flight
(TOF) mass spectrometry imaging of the same section.
Tissue preparation- mouse orthotopic models. Human U87- Animal models were
prepared by intracranial injections of human U87 glioma cells or murine PVL311
neural stem cells (derived from embryonic brains of p53-null mice and transformed
to express human B-RAF V600E point mutation), both lines engineered to
Figure 4 | CD31 staining of blood vessels in mouse brain with PVL311
xenograft tumor. Cluster of differentiation 31 (CD31) antibody staining
was applied to stain the normal and abnormal blood vessels in PVL311
tumor. Abnormal blood vessels are swollen and the endothelial cells
stained by CD31 in tumor are not well organized as in normal blood vessels
in the image.
Figure 5 | The structures of erlotinib and its possible metabolites. The chemical compositions and positively charged ion mass are included. The
pharmacologically activemetaboliteM14 and its isomerM13 are highlighted in yellow.Organs inwhich themetabolites were detected are indicated below
each metabolite. In total, 10 metabolites out of the 14 metabolites reported by Ling et al35 were directly detected by MALDI FTICR MSI.
www.nature.com/scientificreports
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overexpress luciferase. Tumor growth was monitored by in vivo bioluminescence
imaging, after intra-peritoneal (I.P.) injection of luciferin at 225 mg/kg (mice sedated
via inhalation of ,3% isoflurane). The animals were imaged using a CCD camera
after 10 minutes. After documentation of tumor growth, the animals were treated by
oral gavage of therapeutic levels of drug, and sacrificed at half-point to the in vivo half-
life of the active compound. The animals were promptly dissected and liver, kidney,
and brain were flash frozen in liquid nitrogen. Sections with 10 mm thickness were
collected for mass spectrometry and histochemistry analysis. All animal experiments
were approved by the Dana Farber Animal Care and Use Committee and distress to
animals was minimized. Tissue sections were transferred using a brush onto indium
tin oxide (ITO) coated glass slides for mass spectrometry imaging or optical slides for
immunohistochemistry and hematoxylin and eosin (H&E) staining.
Matrix preparation. The ImagePrep (BrukerDaltonics, Germany), which can spray
matrix solution homogeneously, was used formatrix deposition on ITO coated slides.
The matrix solution was 30 mg/mL 2,5-dihydroxybenzoic acid dissolved in 50%
HPLC grade methanol, 50% HPLC grade water and 0.2% trifluoroacetic acid. The
solution was sonicated for 5 min and centrifuged at 10,000 rpm for 10 min before
transferred to the ImagePrep. The ITO coated slides from 280uC freezer were
dehydrated in a dessicator for 15 min upon thawing. Thematrix was sprayed onto the
slides by piezoelectric nebulization in ImagePrep with approximately 85 thin layers of
matrix deposition. Chemicals were purchased from Sigma (Sigma-Aldrich, St. Louis,
MO).
MALDI TOF mass spectrometry. MALDI TOF imaging was performed using the
UltrafleXtreme MALDI TOF/TOF (Bruker Daltonics, Germany) in positive
reflectron ion mode with a 1 KHz smartbeam laser. The instrument was calibrated
with peptide calibration standard (Bruker Daltonics, Germany) for m/z 700–1800.
Tissue sections were imaged with spatial resolution from 25–100 mm. Each spectrum
was acquired from 200 or 300 laser shots. The MALDI images were displayed using
the software FlexImaging 3.0.
MALDI FTICR mass spectrometry. The tissue sections analyzed by MALDI q-
FTICR mass spectrometry (Apex-Ultra, Bruker, MA) were imaged with 45 mm to
220 mm laser raster. Instruments with magnetic fields from 7.0–12.0 T were used,
with the infinity ion cyclotron resonance cell geometry36, dual MALDI/electrospray
source (Apollo II), and vacuum elements with readings of below 43 10210mbar in the
analyzer region. The instrument was calibrated in ESI mode using 0.01 mg/mL
sodium formate (Sigma-Aldrich, St. Louis, MO) solution in 50% acetonitrile 0.1%
formic acid. However, the imaging experiment was performed under MALDI mode.
Mass spectrometry experiments involved the following steps. Initially MALDI source
and transfer parameters were optimized for maximum signal magnitude. Next,
excitation amplitude was tuned for maximum accuracy under internal calibration
conditions37. Sidekick trapping38 was employed. Chirp excitation and image charge
detection was performed. The free induction decay (FID) wasmultiplied by a sine bell
apodization function and was fast Fourier transformed. The mass range for the filters
was m/z 6 0.001 and the intensity range were 100,000 to 1,000,000 which was set to
avoid picking noise signal and was tested in negative controls. The theoretical masses
and molecule fine structures were calculated and predicted by a lab-developed
software39.
Fluorescence microscopy. Fluorescence imaging was performed on the same tissue
as for MALDI MSI prior to MALDI matrix spraying. Fluorescein and fluorescein
isothiocyanate (FITC), two BBB impermeable fluorophores have excitation
maximum of 490 nm and 492 nm, and emission maximum at 518 nm and 514 nm
respectively. Fluorescence images were acquired using a fluorescent microscope
Observer.Z1 with the X-Cite 120Q series light source and AxioCam MRm mounted
camera (Zeiss, Germany) with 53 objective, optovar of 1.6, and 1 s exposure time.
Histochemistry. The tissue morphological information was revealed on sister
sections of the ones for MS imaging using standard hematoxylin and eosin staining
(H&E Staining). All the reagents used for staining were from Sigma (Sigma-Aldrich,
St. Louis, MO). After the sections were dried, toluene was applied and the slides and
covered with glass coverslips. The optical images of tissues were scanned by Axio
Imager M1 microscope (Zeiss, Chester, VA) at 403 magnification. The detailed
morphology information of healthy sections and tumors was evaluated on the Mirax
Digital Slide Desktop Server system.
Data analysis and 3D reconstruction. For the images obtained from MALDI
imaging, heme and various drugs have identical maximum absolute intensity
threshold respectively. The minimum intensity threshold is based on examining
individual imaging pixels until showing reasonable S/N ratio in spectrum for each
image. 3DDoctor is used for 3D reconstruction ofMS images and optical images. For
RAF265 study, the 3D models of heme, drug and histological images are built
individually. However, for BKM120, heme and drug images from the same brain
tissue are considered as consecutive sections and reconstructed within one model. In
reconstructedmodels, heme and drug distributions are highlighted using the function
of ‘‘interactive segment’’ in 3DDoctor (Able Software Corp., Lexington,MA) without
displaying intensity discrepancy. The reconstruction of optical images is based on
drawing outlines of regions of interest manually.
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